Loading news...
Amy Bachrodt exercised 5,000 shares and immediately sold them for approximately $227,612 on Jan. 22, 2026. Maze Therapeutics' stock surged 157% in 2025, its first year on the stock market.
Maze Therapeutics leverages its Compass platform to translate human genetic insights into de-risked, high-probability drug candidates. MZE829 targets APOL1-mediated kidney disease with a dual inhibition strategy, potentially surpassing Vertex's first-mover approach; Phase 2 HORIZON data is expected in Q1 FY2026. MAZE's pipeline includes MZE782 for phenylketonuria and CKD, plus a promising 'skinny gene' obesity program targeting nutrient absorption.
Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) CMO Harold Bernstein sold 25,156 shares of the company's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total value of $1,011,271.20. The transaction was disclosed in a document filed with the Securities and Exchange Commission,
A Maze insider recently exercised 72,500 shares and then immediately sold them for an aggregate transaction value of approximately $2.94 million. As such, the shares originated from option exercises that were fully vested and immediately liquidated.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the company's stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $40.08, for a total value of $200,400.00. Following the sale, the senior vice president owned 12,965 shares in the company, valued
Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) SVP Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the sale, the senior vice president directly owned 12,965 shares of the company's
Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) CMO Harold Bernstein sold 45,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00. The sale was disclosed in a legal filing with the SEC, which is available at
Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) insider Atul Dandekar sold 72,400 shares of the company's stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider owned 10,503 shares of the company's stock, valued at
Shares of Maze Therapeutics, Inc. (NASDAQ: MAZE - Get Free Report) have been assigned a consensus rating of "Buy" from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and three have given a strong buy
Ensign Peak Advisors Inc purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 18,539 shares of the company's stock, valued at approximately $227,000. Several other institutional investors and hedge funds have also made changes to
Maze Therapeutics, Inc. ( MAZE ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:00 AM EST Company Participants Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma.
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the third quarter ended September 30, 2025, highlighting recent progress and business updates.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the American Society of Nephrology's (ASN) Kidney Week, being held November 6-9 in Houston, Texas.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November 11, 2025, at 9:30 a.m.
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D.
Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
Maze Therapeutics, Inc. (NASDAQ:MAZE ) MZE782 Phase 1 Healthy Volunteer Trial Results Conference September 11, 2025 08:30 AM ET Company Participants Amy Bachrodt Jason Coloma - CEO & Director Harold Bernstein - President of Research & Development and Chief Medical Officer Misbah Tahir - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Presentation Operator Good morning.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses.